drug · small molecule
apixaban
pre_registrationupdated 5mo agoby Taho Pharmaceuticals Ltd🔗 ChEMBL
community read0 votes
🐶 often sniffed alongside
top 8- drugapixaban ER5 co-mentions · 2 sources
- drugapixaban ODT5 co-mentions · 2 sources
- tagOncology2 co-mentions · 1 sources
- tagHematology2 co-mentions · 1 sources
- tagAdCom2 co-mentions · 1 sources
- tag510(k) Clearance2 co-mentions · 1 sources
- tagDiagnostics Company2 co-mentions · 1 sources
- companyMedical University of Gdansk1 co-mentions · 1 sources
Small molecule drug with a maximum clinical stage of Approval (across all indications), with 8 approved and 14 investigational indications.
targets
Coagulation factor X
all catalysts(0)
nothing on the calendar yet
Trials studying apixaban
- phase3Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation
- phase1Single Dose Trial of VMX-C001 in Healthy Subjects With and Without FXa Direct Oral Anticoagulant
- N/ADEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosis
- phase2Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation
- phase3Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers
- phase3A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
- phase1A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Participants
- phase3REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults
News(10)
- BMO most bullish on Merck's, bearish on BMS’ plans to contend with patent cliffsBMO Capital Markets is more impressed by Merck’s plans to replace lost Keytruda revenue than on Bristol Myers Squibb’s efforts to fill the expected void that will come from loss of exclusivity for…biospace · 2d ago
- Bristol Myers trial revisions shake confidence in new class of fibrosis drugsA spokesperson confirmed that a “limited number” of liver-related safety events, including a patient death, were observed in testing of Bristol Myers’ admilparant — though it’s unclear whether the…biopharma_dive · 4d ago
- August biopharma layoffs impact just over 500, down 90% year over yearLast month, biotech and pharma companies making or planning workforce cuts included three whose reductions will more than halve their workforces. Blueprint Medicines’ layoffs will affect the most e…biospace · 24d ago
- Stripped of AstraZeneca safety net, BMS could face ‘carnage’ if high-risk clinical trial failsBMS is barreling toward a clinical trial readout that an H.C. Wainwright analyst believes could contribute to the return of mergers between mega-cap drugmakers.biospace · 1mo ago
- BMS picks Texas for new $2.3B manufacturing campusBristol Myers Squibb’s $2.3 billion Houston manufacturing campus is part of the company’s larger $40 billion investment designed to bolster American innovation and manufacturing.biospace · 1mo ago
- Earnings roundup: Gilead’s ‘uncertain’ future, Pfizer’s crossroads and Merck’s PCSK9 launchSome analysts see warning signs in crucial drug launches from Gilead and Merck, while an important trial readout could change Pfizer’s growth trajectory.biopharma_dive · 2mo ago
- No deal between AstraZeneca and BMS, senior source insists: ReutersReuters has deflated rumors that AstraZeneca and Bristol Myers Squibb are discussing a possible merger, letting the air out of industry-wide speculation over what could have been the largest deal i…biospace · 2mo ago
- Rumors of biggest pharma merger ever drop amid Q2 earnings, contentious FDA adcommsThe industry has been abuzz since the weekend when talks of a potential mega-merger between Bristol Myers Squibb and AstraZeneca were reported. Meanwhile, Pfizer, Merck and others release second qu…biospace · 2mo ago
- Pfizer CEO defends $7B bolt-on M&A strategy as peers rush to buyAsked on a second quarter earnings call if Pfizer could direct more money to M&A amid a feeding frenzy across the pharma industry, CEO Albert Bourla defended his strategy.biospace · 2mo ago
- Pfizer expands multibillion-dollar cost-cutting planHatched three years ago, the restructuring is now expected to deliver $1 billion in new cost reductions and save Pfizer another $1.5 billion by streamlining drug production.biopharma_dive · 2mo ago
Data sources
last refreshed 15m ago
Found something off?
comments(0)
5-min edit window · permanent after that